Successful treatment of an anti-MDA5 antibody-positive Juvenile Dermatomyositis patient with refractory interstitial lung disease using tofacitinib.
Natoli V,Palmeri S,Rebollo-Giménez A,Matucci-Cerinic C,Bocca P,Caorsi R,Volpi S,Papa R,Consolaro A,Gattorno M,Ravelli A,Rosina S
Source :
2025 Feb 26
Pmid / DOI:
40001174
Abstract
KEYWORDSAnti-MDA5 antibodies, Interstitial lung disease, JAK inhibitors, Juvenile dermatomyositis, Tofacitinib, Type I IFN gene signature